VBIV vs. NRBO, COCP, HUGE, NERV, AYTU, VAXX, TNXP, ORGS, TLPH, and AVTX
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include NeuroBo Pharmaceuticals (NRBO), Cocrystal Pharma (COCP), FSD Pharma (HUGE), Minerva Neurosciences (NERV), Aytu BioPharma (AYTU), Vaxxinity (VAXX), Tonix Pharmaceuticals (TNXP), Orgenesis (ORGS), Talphera (TLPH), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical preparations" industry.
VBI Vaccines (NASDAQ:VBIV) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
NeuroBo Pharmaceuticals has lower revenue, but higher earnings than VBI Vaccines.
In the previous week, NeuroBo Pharmaceuticals had 1 more articles in the media than VBI Vaccines. MarketBeat recorded 3 mentions for NeuroBo Pharmaceuticals and 2 mentions for VBI Vaccines. VBI Vaccines' average media sentiment score of 0.55 beat NeuroBo Pharmaceuticals' score of 0.13 indicating that VBI Vaccines is being referred to more favorably in the media.
VBI Vaccines has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500.
12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by insiders. Comparatively, 0.8% of NeuroBo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
VBI Vaccines received 474 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. Likewise, 74.74% of users gave VBI Vaccines an outperform vote while only 74.29% of users gave NeuroBo Pharmaceuticals an outperform vote.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to VBI Vaccines' net margin of -1,069.29%. NeuroBo Pharmaceuticals' return on equity of -59.42% beat VBI Vaccines' return on equity.
Summary
VBI Vaccines beats NeuroBo Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
